Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
91% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ATRS: No Debt )
ATRS' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.67
ATRS's Equity to Asset is ranked higher than
77% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ATRS: 0.67 )
ATRS' s 10-Year Equity to Asset Range
Min: -4.09   Max: 0.95
Current: 0.67

-4.09
0.95
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
93% of the 209 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.30 vs. ATRS: No Debt )
ATRS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 2.68
M-Score: -4.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -138.72
ATRS's Operating margin (%) is ranked higher than
50% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.14 vs. ATRS: -138.72 )
ATRS' s 10-Year Operating margin (%) Range
Min: -1709.11   Max: -26.96
Current: -138.72

-1709.11
-26.96
Net-margin (%) -137.21
ATRS's Net-margin (%) is ranked higher than
52% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. ATRS: -137.21 )
ATRS' s 10-Year Net-margin (%) Range
Min: -1728.74   Max: -26.66
Current: -137.21

-1728.74
-26.66
ROE (%) -43.53
ATRS's ROE (%) is ranked higher than
56% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. ATRS: -43.53 )
ATRS' s 10-Year ROE (%) Range
Min: -6822.87   Max: -19.42
Current: -43.53

-6822.87
-19.42
ROA (%) -34.49
ATRS's ROA (%) is ranked higher than
54% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. ATRS: -34.49 )
ATRS' s 10-Year ROA (%) Range
Min: -530.86   Max: -15.37
Current: -34.49

-530.86
-15.37
ROC (Joel Greenblatt) (%) -437.87
ATRS's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.21 vs. ATRS: -437.87 )
ATRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2300.72   Max: -395.82
Current: -437.87

-2300.72
-395.82
Revenue Growth (%) 2.20
ATRS's Revenue Growth (%) is ranked higher than
70% of the 280 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ATRS: 2.20 )
ATRS' s 10-Year Revenue Growth (%) Range
Min: -63.4   Max: 89.8
Current: 2.2

-63.4
89.8
EBITDA Growth (%) 31.70
ATRS's EBITDA Growth (%) is ranked higher than
94% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. ATRS: 31.70 )
ATRS' s 10-Year EBITDA Growth (%) Range
Min: -41.9   Max: 31.7
Current: 31.7

-41.9
31.7
EPS Growth (%) 31.70
ATRS's EPS Growth (%) is ranked higher than
91% of the 241 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. ATRS: 31.70 )
ATRS' s 10-Year EPS Growth (%) Range
Min: -58.1   Max: 31.7
Current: 31.7

-58.1
31.7
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ATRS Guru Trades in Q3 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q4 2013

ATRS Guru Trades in Q4 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q1 2014

ATRS Guru Trades in Q1 2014

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q2 2014

ATRS Guru Trades in Q2 2014

Jean-Marie Eveillard 20,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-06-30 Sold Out $2.63 - $3.3 $ 1.98-35%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.60
ATRS's P/B is ranked higher than
62% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ATRS: 4.60 )
ATRS' s 10-Year P/B Range
Min: 2.26   Max: 77.5
Current: 4.6

2.26
77.5
P/S 11.65
ATRS's P/S is ranked higher than
55% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ATRS: 11.65 )
ATRS' s 10-Year P/S Range
Min: 3.56   Max: 36
Current: 11.65

3.56
36
Current Ratio 3.13
ATRS's Current Ratio is ranked higher than
80% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.78 vs. ATRS: 3.13 )
ATRS' s 10-Year Current Ratio Range
Min: 0.11   Max: 17.17
Current: 3.13

0.11
17.17
Quick Ratio 2.76
ATRS's Quick Ratio is ranked higher than
82% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. ATRS: 2.76 )
ATRS' s 10-Year Quick Ratio Range
Min: 0.09   Max: 16.5
Current: 2.76

0.09
16.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.00
ATRS's Price/Net Cash is ranked higher than
93% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ATRS: 9.00 )
ATRS' s 10-Year Price/Net Cash Range
Min: 1.18   Max: 108
Current: 9

1.18
108
Price/Net Current Asset Value 7.33
ATRS's Price/Net Current Asset Value is ranked higher than
89% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ATRS: 7.33 )
ATRS' s 10-Year Price/Net Current Asset Value Range
Min: 1.01   Max: 108
Current: 7.33

1.01
108
Price/Tangible Book 4.95
ATRS's Price/Tangible Book is ranked higher than
72% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.59 vs. ATRS: 4.95 )
ATRS' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 44.5
Current: 4.95

0.62
44.5
Price/Median PS Value 0.90
ATRS's Price/Median PS Value is ranked higher than
86% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.08 vs. ATRS: 0.90 )
ATRS' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.49
Current: 0.9

0.08
2.49
Forward Rate of Return (Yacktman) 0.49
ATRS's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. ATRS: 0.49 )
ATRS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 40.6   Max: 117.6
Current: 0.49

40.6
117.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MJC.Germany
Antares Pharma, Inc., formerly known as Medi-Ject Corporation, or Medi-Ject, is a specialty pharmaceutical company developing and commercializing self-administered parenteral pharmaceutical products and technologies and topical gel-based products. It develops both subcutaneous and intramuscular injection technology systems including Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. The Company has licensed its reusable needle-free injection device for use with human growth hormone to Teva Pharmaceutical Industries, Ltd., Ferring Pharmaceuticals BV and JCR Pharmaceuticals Co., Ltd., with Teva and Ferring being two of the Company's primary customers. The Company's needle-free injection device is marketed by Teva as the Tjet injector system to administer their 5mg Tev-Tropin brand hGH marketed in the U.S. The Company's needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet 2 Vision and Zomajet Vision X, respectively, in Europe and Asia. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. The Company's product candidate, OTREXUP, is a proprietary combination product comprised of a pre-filled methotrexate syringe and the Company's Medi-Jet self-injection system for the treatment of moderate to severe rheumatoid arthritis. It is also developing Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency and has conducted a pre-IND meeting with the FDA as part of preparing to initiate clinical development for this product. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, and Novartis.
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Sep 15 2014
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer Sep 15 2014
Antares Pharma to Participate at the Morgan Stanley Healthcare Conference Sep 03 2014
ANTARES PHARMA, INC. Financials Aug 15 2014
Q2 2014 Antares Pharma, Inc. Earnings Release - Before Market Open Aug 07 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Aug 07 2014
Antares Pharma Reports Second Quarter 2014 Operating and Financial Results Aug 07 2014
Antares Pharma to Host Second Quarter 2014 Operating and Financial Results Conference Call Jul 31 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 22 2014
Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating... Jul 22 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Other Events Jul 11 2014
Antares: Uncertainty Creates An Exceptional Buying Opportunity Jul 08 2014
Rapid Restoration and Consistent Maintenance of Steady Blood Levels Achieved with Once-Weekly... Jun 25 2014
Antares Pharma (ATRS) Crumbles: Stock Falls by 8.3% Jun 25 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 24 2014
Antares Pharma Announces Changes in Senior Leadership Jun 24 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 04 2014
Otrexup Sales Trajectory Points To First Profitable Quarter For Antares Pharma In 2015 May 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK